Skip to main content

Myocardial Infarction- Etiology, Pathogenesis, Clinical Diagnosis and Management!

MYOCARDIAL INFARCTION

Definition:

  • Myocardial Infarction is defined as " a diseased condition which is caused by reduced blood flow to the coronary artery due to atherosclerosis and occlusion of artery by embolus or thrombus."

Myocardial Infarction (or Heart attack) is the irreversible damage of myocardial tissue due to prolonged ischemia or hypoxia.

Universally accepted definition of MI: Evidence of myocardial necrosis in consistent with the myocardial ischemia, in which case any of the following meets the diagnosis of Myocardial Infarction.

  1. Evidence rises and/or fall of cardiac biomarkers (preferably troponin).
  2. ECG changes indicative of new ischemia (new ST-T changes or new left bundle branch block)
  3. Development of pathological Q waves.
  4. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.


Etiology:

  • Tobacco smoking
  • Diabetes Mellitus
  • Age
  • Hypertension
  • Obesity
  • Gender
  • Stress
  • Drug abuse
  • Alcohol consumption
  • Family history of ischemic heart disease (IHD)
  • Chronic Kidney Disease (CKD)
  • Hyperhomocystenima
  • Hyperlipoproteinemia

Etiopathogenesis:

  1. Acute plaque rupture
  2. Myocardial ischemia
  3. Non-atherosclerotic cause
  4. Transmural v/s subendocardial infarcts
  5. Role of platelets

 Pathophysiology

Clinical Presentation:

  • Chest pain
  • Dyspnea
  • Fatigue
  • Sweating
  • Weakness
  • Nausea
  • Vomiting
  • Light headache
  • Palpitation
  • Anxiety
  • Sleeplessness
  • Hypertension
  • Hypotension
  • Arrythmias

Complications:

  • Arrythmias
  • Cardiogenic shock
  • Congestive Heart failure
  • Thromboembolism
  • Pericarditis

Diagnosis/Investigation:

  1. Clinical Features: Apprehension, Fever, Pain, Shock, Indigestion.
  2. Serum cardiac Markers: 
  • Creatinine phosphokinase (CK)
  • Lactic dehydrogenase (LDH)
  • Cardiac specific troponins (CTN)

      3. ECG changes: ST segment elevation, T wave inversion, Appearance of wide deep Q wave.

      4.Other Tests: MRI, Angiography, Position emission tomography (PET scan). Chest X-ray, Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP).

Management:

1.Non-Pharmacological Treatment:

  1. Counselling and education to patients.
  2. Alcohol consumption cessation.
  3. Smoking cessation
  4. Lifestyle measurement
  5. Diet and nutrition
  6. Salt Restriction

2.Pharmacological Treatment:

  1. Anti-Thrombolytic Therapy: 

  • Antiplatelets-to reduce the aggregation of platelets such as Aspirin, Clopidogrel, Ticagrelor.
  • Anti-coagulants- that reduces the risk of thromboembolic complication and prevents reinfarction in the absence of reperfusion therapy. 

      2. Anti-hypertensive agents:

  • Glyceryl trinitrate sublingual, IV nitrates

      3. Lipid Lowering Agents:

  • Reduction of cholesterol through diet and drugs helps reducing morbidity and mortality.

      4. Vasodilators: 

  • Beta blockers

      5. Others:

  • such as Analgesics, IV Opiates (morphine sulphate or diamorphine 2.5-5mg), IV anti-emetics (initially metoclopramide 10mg), Anti-ulcers, Antidepressants

      6. Reperfusion Therapy:

  • Depending on the type of MI, outcome of reperfusion therapy varies: 

          NSTEMI (Non-demonstrable benefit)

          STEMI (Restores coronary artery patency, improves ventricular function and improves survival)

      7. Percutaneous Coronary Intervention (PCI)

      8. Thrombolysis: 

  • It reduces hospital mortality by 20-50%. 
  • Alteplase (human tissue plasminogen activator). over 90 minutes (15mg bolus dose), followed by 0.75mg/kg bodyweight not exceeding 50mg over 30 minutes. Then 0.5mg/kg body weight, not exceeding 35mg over 60 minutes. 
  • This has better survival rate than other thrombolytics.




Labels:

Comments

Post a Comment

Popular posts from this blog

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD)
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-50mg/dL and A1c level
Post a Comment
Read more

GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)!

MANAGEMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE  "GERD refers to the endoscopically determined esophagitis or endoscopy-negative reflux disease" . "GERD is the term used to describe any symptomatic clinical condition or histopathological alteration resulting from episodes of reflux of acid, pepsin and occasionally, bile into the esophagus from the stomach". Patients with uninvestigated "reflux-like" symptoms should be managed as patients with uninvestigated dyspepsia. There is currently no evidence that H.pylori should be investigated in patients with GERD. Symptoms: Heartburn is the characteristic symptom of GERD. Acid regurgitation Dysphagia Belching Upper abdominal discomfort Bloating and postprandial fullness Chest pain Hoarseness Cough Complications include: Esophageal ulceration Formation of specialized columnar-lined esophagus at the gastro-esophageal junction known as Barretts Esophagus . Mechanism of Acid Reflux: The mechanism of acid reflux is mu
Post a Comment
Read more